Relevant bibliographies by topics / Chemotherapy (CT)

Academic literature on the topic 'Chemotherapy (CT)'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Chemotherapy (CT).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Chemotherapy (CT)"

1

Tomaro, Maria, Paula Silverman, Wendy Rowehl Miano, Amy Wakeling, and Kathleen Gonzalez. "Chemotherapy safety initiative." Journal of Clinical Oncology 31, no. 31_suppl (November 1, 2013): 226. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.226.

Full text
Abstract:
226 Background: The 2006 Institute of Medicine report "Preventing Medication Errors," stated that “medication errors harm at least 1.5 million patients every year…” Chemotherapy (CT) has a narrow therapeutic index and safety margin which can and does lead to fatal errors. University Hospitals Seidman Cancer Center (UHSCC), an National Cancer Institute (NCI) designated Comprehensive Cancer Center, dispensed 10,500 CT doses in 2012 and has taken an active approach to enhance CT safety. Methods: In the last quarter of 2012, a nurse coordinator (NC) for chemotherapy orders and a Chemotherapy Safety Governance Committee (CSGC) was conceptualized. The NC’s role would be to incorporate CT safety best practices into order set development. The charter for the CSGC includes 1) to establish cancer CT standards and operating procedures across the adult and pediatric oncology population; 2) to develop and oversee cancer CT order set infrastructure applicable to our hybrid electronic/paper current state; and 3) to lead performance improvement initiatives related to CT safety. Leading organizations involved in oncology practice and medication safety standard-setting (ASCO, Oncology Nursing Society, Institute For Safe Medication Practices, National Comprehensive Cancer Network, Journal of Cancer Research) were reviewed for recommendations for standards for CT order sets. Results: Thirty standards for a CT order template were identified by the NC. A comprehensive gap analysis was completed to compare the current inpatient and ambulatory CT order sets to these standards. Results of the gap analysis were brought to the CSGC, a multi-disciplinary group of cancer and quality clinicians and leaders over 6 meetings. Consensus was achieved on the application of these standards to CT order sets. Our new orders will adopt 100% of all identified standards for CT orders. Conclusions: The gap analysis led to the development of a CT order set template that maximizes safety by applying best-practice standards. This template is designed to be applicable to electronic and paper-based order sets and with minor variation, appropriate to all disease-based order sets. This template is currently being utilized to revise 330 electronic and 398 paper CT order sets at UHSCC. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
2

Robinson, S. I., J. Murray, and R. R. McWilliams. "Celiac disease and chemotherapy." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 19561. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.19561.

Full text
Abstract:
19561 Background: Diarrhea is a common side effect of chemotherapy (CT). At times, often unpredictably, patients develop profound diarrhea during CT. Though the clinical diagnosis of celiac disease (CD) is relatively rare, (1/ 2000), the serologic prevalence is much higher (1/ 133), suggesting a large number of undiagnosed cases. Latent CD may be unmasked by stressors, such as CT. We hypothesized that undiagnosed CD may account for some cases of severe diarrhea from CT. Methods: We performed a retrospective chart review at the Mayo Clinic (1980–2006) for patients with diagnoses of cancer and CD that received CT at our center. CD cases were confirmed by biopsy (n= 25) or serologic studies. Data analyzed included severe (grade ≥ 3,) diarrhea while on CT, site of primary cancer, diagnosis of CD prior to or after CT, and specific CT agents received. Results: We identified 27 patients with CD and cancer (12 lymphoma, 6 gastrointestinal, 2 leukemia, 2 breast, 1 brain, bladder, lung, uterine, sarcoma) who received CT at our center. Fifteen were diagnosed with CD prior to receiving CT and 12 after, with the former group presumably on a gluten-free diet. One patient was excluded for lack of clinical data. Five of remaining 14 patients (35%) managed for their CD prior to CT had diarrhea, though 4 of these 5 had only mild diarrhea (gr. 1). One patient suffered gr. 3 diarrhea, though was reported to be poorly compliant with his diet. Three patients received treatment with 5- fluorouracil (5FU), and 2 had gr. 1 diarrhea. Five of the 12 patients (42%) with celiac disease undiagnosed prior to CT were reported to have diarrhea during treatment (3 gr. 4; 2 gr. 1). Of those receiving 5FU, 3 out of 4 had severe (gr. 4) diarrhea. The small numbers of patients precluded meaningful statistical analysis. Conclusion: Patients with known CD compliant with a gluten-free diet tolerated CT well. However, in a subset of undiagnosed patients, severe diarrhea developed during CT, most notably with 5FU-based regimens. We propose that when patients have diarrhea disproportionate to other effects, CD should be considered. Also, in malignancies with a high incidence of CD such as lymphoma and small bowel cancer, underlying CD should be considered before CT is given. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
3

Rehan, Fareed A., Corinne Brillant, Holger Schulz, Ina Knauel, Julia Bohlius, Lena Specht, and Andreas Engert. "Chemotherapy Alone Versus Chemotherapy Plus Radiotherapy for Early Stage Hodgkin Lymphoma." Blood 110, no. 11 (November 16, 2007): 2320. http://dx.doi.org/10.1182/blood.v110.11.2320.2320.

Full text
Abstract:
Abstract Both chemotherapy (CT) alone and combined modality therapy (CMT) are effective modalities for the treatment of early stages of Hodgkin lymphoma (HL). However, the optimal choice of treatment is still being discussed. Different research groups reported that ABVD-like CT followed by radiotherapy is highly effective for early favourable and early unfavourable (intermediate) stage HL. A recently conducted randomized trial aimed at determining whether CMT is superior to CT alone in early stages, showed no significant difference in 5 year overall survival (OS) and event-free survival in patients treated with either 4–6 cycles of ABVD alone or 2 cycles of ABVD plus radiotherapy. Thus, this systematic review and meta-analysis was performed for a more comprehensive comparison. Methods: Only randomized controlled trials (RCT) comparing CT alone with CMT in newly diagnosed adults with early stages of HL (CS IA, IB, IIA, IIB) were included. Medline and Cochrane Library were systematically searched for randomized controlled trials from 1975 to 2007. Patients who received CMT were considered as experimental group and patients who received ABVD-like CT alone were considered as control group. Data were collected from full text publications or abstracts and treatment effects for OS were calculated as hazard ratios (HR). Results: A total of 590 references were screened. Four eligible RCTs were identified, including 1207 patients with early-stage HL (early favourable and early unfavourable stages). Between 1983 and 2004, 765 patients where treated with CMT and 442 patients with CT alone. The OS for the CMT group was significantly better than the OS for the CT-alone group (HR: 0.54; 95% CI [0.35 - 0.84]; p = 0.006), but there was evidence for a substantial heterogeneity between the studies (I2 = 69%, p=0.02). Discussion: First results of this systematic review showed improved OS for patients treated with CMT in early-stage HL compared to patients treated with CT alone. The substantial heterogeneity between the trials should be clarified. Further comprehensive analyses are ongoing and will provide more detailed information.
APA, Harvard, Vancouver, ISO, and other styles
4

Debled, M., A. Trainaud, M. Durand, A. Floquet, V. Brouste, and L. Mauriac. "Administration of further chemotherapy (CT) after capecitabine as first-line chemotherapy (CT) for metastatic breast cancer (MBC)." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 1095. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1095.

Full text
Abstract:
1095 Background: Based on results of randomized trials of Xeloda (X) vs CMF or taxanes (T) as first-line CT for MBC, very favorable tolerability, and patients’ (pts) preference for oral therapy, front-line X is now often used in our institution, especially for slowly progressing disease. As other CT regimens, especially T, have demonstrated improved OS, we analyzed post-X CT in these pts. Methods: Analysis was restricted to pts who began X before Jan 05, all of whom have now discontinued because of progression or toxicity. Results: In 90 eligible pts, median TTF and OS from initiation of X are 9 [95% CI 7–11] and 26 [22–30] months, respectively. 75% of pts received second-line CT. Three subgroups can be analyzed: (A) 65 pts (median age 58y, range 34–84) received further CT (median 2 regimens, range 1–6) after stopping X, including T (85% of pts), anthracycline (a/c: 42%), vinorelbine (45%), or mitomycin C (20%). 24 pts received =2 regimens including a/c and T; 7 pts received neither T nor a/c (vinorelbine, n = 6; UFT, n = 1). Median OS from initiation of X was 30 months [95% CI 27–32]. 30 pts are alive after a 16-month median follow-up since X failure; they may receive another CT; (B) 3 pts are currently receiving endocrine therapy after X failure and may receive another CT later; (C) 22 pts (24%) (median age 77y, 19 =70y) died without receiving further CT. Median OS from initiation of X was 11 months (range 0.5–23). 4 of these pts (aged 57, 71, 74, and 84y) received endocrine therapy for 2–10 months. Ability to administer further CT varies with age: of pts <75y, 89% received subsequent CT (T: 75%), whereas 37% of pts =75y received second-line CT. Conclusions: TTF and OS indicate that capecitabine is very active as first-line CT for MBC. For a large majority of pts <75y, first-line X does not compromise administration of further CT including T. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
5

Zhu, Yunshu, Sheng Yang, Shengyu Zhou, Jianliang Yang, Yan Qin, Lin Gui, Yuankai Shi, and Xiaohui He. "Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883592095373. http://dx.doi.org/10.1177/1758835920953738.

Full text
Abstract:
Background: Palliative chemotherapy has been the mainstay treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). However, little is known about the efficacy and toxicity of nimotuzumab (NTZ) – a monoclonal antibody drug targeting epidermal growth factor receptor – plus chemotherapy (CT) versus CT alone for these patients. Methods: The database at Cancer Hospital of Chinese Academy of Medical Sciences was queried for patients diagnosed with NPC who received CT with or without NTZ between 2004 and 2018. Treatment compliance, survival outcomes, and adverse effects were compared among these groups. Results: Records of 70 patients with R/M-NPC were reviewed: 21 (30%) received NTZ plus CT (NTZ+CT) and 49 (70%) received CT. CT regimens included gemcitabine plus platinum, taxane plus platinum (TP), and fluorouracil plus platinum. Comparing the CT group with NTZ+CT group, the median follow up was 62 months (range = 3–133) versus 59 months (range = 9–117); median progression free survival was 7.5 [95% confidence interval (CI) 6.552–8.381] months versus 8.5 (95% CI 6.091–10.976) months, p = 0.424; median overall survival (OS) was 25.6 (95% CI 18.888–32.379) months versus 48.6 (95% CI 35.619–61.581) months, p = 0.017, respectively. Multivariable analysis established treatment group (CT versus NTZ+CT) as an independent prognostic factor for OS (hazard ratio, 0.5; 95% CI 0.255–0.979; p = 0.043). No significant difference with regard to toxicities was observed between the two groups. Among them, a subgroup analysis was performed in 53 (75.7%) patients who received TP with or without NTZ, which showed similar results. Conclusion: Our findings suggested that NTZ+CT provides a novel treatment option and prolongs survival significantly for R/M-NPC.
APA, Harvard, Vancouver, ISO, and other styles
6

Ali, Maria, M. Christine Cripps, Katelyn Balchin, Jennifer Spencer, and Paul Wheatley-Price. "Palliative inpatient chemotherapy: Clinical benefit or harm?" Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e19527-e19527. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e19527.

Full text
Abstract:
e19527 Background: Palliative chemotherapy (CT) is given with the goals of palliating cancer symptoms and prolonging life. Patients with a poor performance status (PS) generally derive less benefit from CT and may experience greater toxicity. Advanced cancer patients admitted to hospital generally have a poor PS, and yet palliative CT is often administered to hospitalized patients. The evidence to support palliative CT in hospitalized patients is scarce. We hypothesize that palliative in-patient CT does not result in meaningful clinical benefit. Methods: With ethics approval, a retrospective chart review was undertaken to report outcomes from in-patient CT at the Ottawa Hospital Cancer Centre between April 2008- January 2010. From hospital pharmacy records, all advanced solid tumor patients receiving in-patient palliative CT were identified. Patients receiving radical, curative, neo- or adjuvant therapy, or those admitted for an inpatient regimen, were excluded. The primary endpoints were overall survival following CT, place of discharge from hospital, and whether further CT was received. Results: We report 199 in-patients (23% breast cancer, 22% small cell lung cancer, 16% NSCLC, 39% other) who received CT (median 1 cycle, range 1-5) during the study period. The median age was 61 (range 19-88); 59% were female. The main reasons for hospital admission were dyspnea (31%) or pain (29%). At baseline 25% were anemic, 36% had leucocytosis and 70% were hypoalbuminemic (<30g/l). 67% were receiving 1st line CT. The median overall survival was 4.5 months (95% CI: 3.2 - 5.8). Longest survival was seen in SCLC patients (7.3m). 77% of patients were discharged home, but 17% died during the admission. 72% of patients received further systemic therapy. Factors significantly associated with shorter survival were hypoalbuminemia (HR 1.52, 95% CI 1.06- 2.18, p=0.02), and therapy in 2nd line or beyond (HR 2.10, [1.37-3.23], p<0.001). Receiving treatment beyond 1st line, and baseline leucocytosis, were both significantly associated with patients being less likely to be discharged home or receive further CT. Conclusions: While in-patient palliative CT is associated with short survival, many patients remain well enough to be discharged home and receive further therapy.
APA, Harvard, Vancouver, ISO, and other styles
7

Landre, Thierry, Kader Chouahnia, Gaëtan Des Guetz, Boris Duchemann, Jean-Baptiste Assié, and Christos Chouaïd. "First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883592097713. http://dx.doi.org/10.1177/1758835920977137.

Full text
Abstract:
Introduction: Platin-based chemotherapy (CT) has long been the first-line standard-of-care for patients with extensive-stage small-cell lung cancer (ES–SCLC). Adding immune-checkpoint inhibitor(s) to CT (ICI+CT) in this setting is an option of interest, although its benefit is apparently modest. Methods: This meta-analysis was conducted on randomized trials comparing first-line ICI+CT versus CT alone for ES–SCLC. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), response at 12 months and adverse events (AEs). Subgroup analyses were computed according to the immunotherapy used, performance status (PS), age, platinum salt, liver metastases and brain metastases at diagnosis. Results: The literature search identified one randomized phase II (ECOG-ACRIN-5161) and four phase III trials (CASPIAN, IMPOWER-133, KEYNOTE-604 and Reck et al. 2016) that included 2775 patients (66% males, 95% smokers, median age: 64 years, PS = 0 or 1). ICI+CT was significantly associated (hazard ratio [95% confidence interval]) with prolonged OS [0.82 (0.75–0.89); p < 0.00001] and PFS [0.81 (0.75–0.87); p < 0.00001], with OS benefits for anti-PD-L1 [0.73 (0.63–0.85); p < 0.0001] or anti-PD-1 [0.76 (0.63–0.93); p < 0.006] but not for anti-CTLA-4 [0.90 (0.80–1.01), p = 0.07]. ORRs for ICI+CT or CT alone were comparable [odds ratio 1.12 (0.97–1.00); p = 0.12], but responses at 12 months favored ICI+CT [4.16 (2.81–6.17), p < 0.00001]. Serious grade-3/4 AEs were more frequent with ICI+CT [odds ratio 1.18 (1.02–1.37); p = 0.03]. Compared with CT, no ICI+CT benefit was found for ES–SCLC with brain metastases at diagnosis [HR 1.14 (0.87–1.50); p = 0.34]. Conclusions: First-line ICI+CT appears to be superior to CT alone for ES–SCLC except for patients with brain metastases at diagnosis.
APA, Harvard, Vancouver, ISO, and other styles
8

Lampe, H., A. Horwich, A. Norman, J. Nicholls, and D. P. Dearnaley. "Fertility after chemotherapy for testicular germ cell cancers." Journal of Clinical Oncology 15, no. 1 (January 1997): 239–45. http://dx.doi.org/10.1200/jco.1997.15.1.239.

Full text
Abstract:
PURPOSE To analyze the probability of recovery of spermatogenesis after orchidectomy and cisplatin-based chemotherapy (CT) for testicular germ cell cancer. PATIENTS AND METHODS One hundred seventy-eight patients treated between 1979 and 1991 were selected by the requirement of sperm count both pre-CT and post-CT. Counts were classified as normospermic (NS) if more than 10 x 10(6)/mL, oligospermic (OS) if 1 to 9 x 10(6)/mL, and azoospermic (AS) if less than 1 x 10(6)/mL. The median follow-up time after CT before sperm analysis was 30 months. RESULTS Analysis of 170 patients whose spermatogenesis was reassessed at least 1 year after CT showed that of 89 patients whose pre-CT counts were NS, the post-CT count was NS in 64%, OS in 16%, and AS in 20%. There was clear evidence for continued recovery beyond 1 year; the probability of spermatogenesis increased to 48% by 2 years and 80% by 5 years. There was a significantly higher probability of recovery to OS and NS count levels in the 54 patients treated with carboplatin-rather than cisplatin-based therapy. There was an independent and similar effect of normal pre-CT count. There was a reduced probability to recover to OS in the 26 patients treated with more than four cycles of CT. A prognostic model identified three groups with 25%, 45%, and 82% probabilities of recovering spermatogenesis by 2 years after CT. CONCLUSION Analysis of pre-CT sperm count together with details of planned treatment can be used to predict recovery of spermatogenesis following germ cell CT.
APA, Harvard, Vancouver, ISO, and other styles
9

Refaie, Huda, Mohamed Sarhan, and Ashraf Hafez. "Role of CT in Assessment of Unresectable Wilms' Tumor Response after Preoperative Chemotherapy in Pediatrics." Scientific World JOURNAL 8 (2008): 661–69. http://dx.doi.org/10.1100/tsw.2008.96.

Full text
Abstract:
The purpose of this study was to define the structural response of unresectable Wilms' tumor following preoperative chemotherapy by computed tomography (CT). We also compared CT changes in relation to histopathological nature. The study included 36 patients with 41 nephroblastomas. All were examined by CT before preoperative chemotherapy using multiphasic CT protocol study. The unresectability was diagnosed by CT imaging. All patients were subjected to fine-needle biopsy (FNB) to confirm the diagnosis and to define the histopathological type before preoperative chemotherapy. Five patients had unfavorable pathology and 31 patients with 36 nephroblastomas had favorable pathology. All patients received first line of treatment. Follow-up of these patients by CT at the 6th week was reviewed. All of our patients were diagnosed as unresectable Wilms' tumor by CT. Preoperative chemotherapy was started. Among our patients, 28 (77.8%) gave good response in the form of significant reduction in tumor size, disappearance of one tumor in two cases with bilateral WT and inferior vena cava (IVC) thrombus, and increased nonenhancing necrotizing content. Two patients with unfavorable pathology did not show any response. The remaining six patients gave partial response. CT can be used to evaluate tumor response and resectability after preoperative chemotherapy with high accuracy. The response to preoperative chemotherapy is not related to the histopathological classifications.
APA, Harvard, Vancouver, ISO, and other styles
10

Yoon, Choon Sik, Myung Jun Kim, Mi Hae Kim, and Ki Keun Oh. "Wilms' tumor:Changes of CT findings after chemotherapy." Journal of the Korean Radiological Society 29, no. 6 (1993): 1331. http://dx.doi.org/10.3348/jkrs.1993.29.6.1331.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Chemotherapy (CT)"

1

Kluge, Regine, Lidia Chavdarova, Martha Hoffmann, Carsten Kobe, Bogdan Malkowski, Françoise Montravers, Lars Kurch, et al. "Inter-reader reliability of early FDG-PET/CT response assessment using the Deauville Scale after 2 cycles of intensive chemotherapy (OEPA) in Hodgkin’s Lymphoma." Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-204087.

Full text
Abstract:
Purpose: The five point Deauville (D) scale is widely used to assess interim PET metabolic response to chemotherapy in Hodgkin lymphoma (HL) patients. An International Validation Study reported good concordance among reviewers in ABVD treated advanced stage HL patients for the binary discrimination between score D1,2,3 and score D4,5. Inter-reader reliability of the whole scale is not well characterised. Methods: Five international expert readers scored 100 interim PET/CT scans from paediatric HL patients. Scans were acquired in 51 European hospitals after two courses of OEPA chemotherapy (according to the EuroNet-PHL-C1 study). Images were interpreted in direct comparison with staging PET/CTs. Results: The probability that two random readers concord on the five point D score of a random case is only 42% (global kappa = 0.24). Aggregating to a three point scale D1,2 vs. D3 vs. D4,5 improves concordance to 60% (kappa = 0.34). Concordance if one of two readers assigns a given score is 70% for score D1,2 only 36% for score D3 and 64% for D4,5. Concordance for the binary decisions D1,2 vs. D3,4,5 is 67% and 86% for D1,2,3 vs D4,5 (kappa = 0.36 resp. 0.56). If one reader assigns D1,2,3 concordance probability is 92%, but only 64% if D4,5 is called. Discrepancies occur mainly in mediastinum, neck and skeleton. Conclusion: Inter-reader reliability of the five point D-scale is poor in this interobserver analysis of paediatric patients who underwent OEPA. Inter-reader variability is maximal in cases assigned to D2 or D3. The binary distinction D1,2,3 versus D4,5 is the most reliable criterion for clinical decision making.
APA, Harvard, Vancouver, ISO, and other styles
2

Kikuchi, Masahiro. "Sequential FDG-PET/CT after Neoadjuvant Chemotherapy is a Predictor of Histopathologic Response in Patients with Head and Neck Squamous Cell Carcinoma." Kyoto University, 2012. http://hdl.handle.net/2433/159394.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Moltz, Jan Hendrik [Verfasser], Horst Karl [Akademischer Betreuer] Hahn, Andreas [Akademischer Betreuer] Nüchter, and Ginneken Bram [Akademischer Betreuer] van. "Lesion segmentation and tracking for CT-based chemotherapy monitoring / Jan Hendrik Moltz. Betreuer: Horst Karl Hahn. Gutachter: Horst Karl Hahn ; Andreas Nüchter ; Bram van Ginneken." Bremen : IRC-Library, Information Resource Center der Jacobs University Bremen, 2013. http://d-nb.info/1087285054/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

BOUIZAR, ZAOR. "Les recepteurs renaux de la calcitonine (ct) : caracterisation, localisation et modifications." Paris 6, 1987. http://www.theses.fr/1987PA066278.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hill, Esme. "Perfusion imaging and tissue biomarkers for colorectal cancer." Thesis, University of Oxford, 2015. https://ora.ox.ac.uk/objects/uuid:4a309265-6f27-4839-9259-f19cf9648c2d.

Full text
Abstract:
Background: Systemic chemotherapy and radiotherapy play an important role in the treatment of colorectal cancer. Tumour perfusion and oxygenation is known to influence radiosensitivity and chemosensitivity. In this thesis, I propose that the evaluation of changes in tumour perfusion using perfusion CT (pCT) and dynamic contrast-enhanced (Dce) MRI can guide the rational sequencing of drugs and radiation. Methods: Dce-MRI and pCT scans were incorporated into a clinical trial of hypofractionated pelvic radiotherapy and nelfinavir in 10 patients with rectal cancer. Toxicity and tissue biomarkers (tumour cell density, microvessel density, CAIX, HIF1-alpha, phospho-Akt and phospho-PRAS40) were evaluated. pCT liver scans were incorporated into an imaging study in patients with colorectal liver metastases randomised to receive either oxaliplatin/ 5FU chemotherapy or oxaliplatin/ 5FU chemotherapy plus selective internal radiotherapy. Results: After 7 days of nelfinavir concurrent with hypo-fractionated pelvic radiotherapy, there was a mean 42% increase in median Ktrans (P=0.03, paired t test) on Dce-MRI and a median 30% increase in mean blood flow on pCT (P=0.028, Wilcoxon Rank Sum), although no statistically significant changes in perfusion parameters were demonstrated after 7 days of nelfinavir prior to radiotherapy. The feasibility of evaluating tumour cell density in rectal biopsies before and after radiotherapy and a radiosensitising drug as an early endpoint of response was demonstrated. In patients with colorectal liver metastases who received oxaliplatin and modified de Gramont chemotherapy alone, after 4 cycles of chemotherapy, a 28% decrease in the mean hepatic arterial fraction was observed (P=0.018, paired t test). Between pCT scans 2 days before SIRT and 39-47 days following SIRT and continued 2-weekly chemotherapy, there was a mean 62% (P=0.009) reduction in Blood Flow and 61% (P=0.006) reduction in Blood Volume (paired t test). Conclusions This research does not support the hypothesis that nelfinavir before radiotherapy improves blood flow to human rectal cancer. Increases in rectal tumour perfusion during radiotherapy and concurrent nelfinavir are likely to be primarily explained by the acute biological effects of radiation. Four or more cycles of oxaliplatin and modified de Gramont chemotherapy may result in changes in tumour perfusion of colorectal liver metastases which would be detrimental to subsequent radiotherapy. Selective internal radiotherapy resulted in substantial reductions in tumour perfusion 39-47 days after the treatment. Perfusion imaging can be used to detect changes in tumour perfusion in response to radiotherapy and systemic therapy which have implications for the sequencing of therapies.
APA, Harvard, Vancouver, ISO, and other styles
6

Sorger, Natalie K. "Volumetrie aus Spiral-CT-Datensätzen zur Response-Evaluation unter neoadjuvanter Chemotherapie bei Tumoren des oesophago-gastralen Überganges und des Magens." [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=966327934.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Engelmann, Kerstin. "CT-gesteuerte perkutane intratumorale Chemotherapie mit einem neuartigen Cisplatin-, Adrenalin-Gel zur Behandlung inoperabler maligner Lebertumoren Ergebnisse einer klinischen Phase-II-Prüfung /." [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=965796841.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lehmann, Mona [Verfasser], and Peter [Akademischer Betreuer] Bartenstein. "Therapieansprechen in der 18F-FDG PET/CT nach kombinierter Chemotherapie und regionaler Tiefenhyperthermie bei Patienten mit Weichteilsarkom / Mona Lehmann ; Betreuer: Peter Bartenstein." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2018. http://d-nb.info/1177681935/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hong, Jia-Wen, and 洪佳雯. "The influence of Huang-Lian-Jie-Du-Tang (HLJDT) combined chemotherapy in BALB/c mice bearing CT-26 tumor." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/45923749503541889810.

Full text
Abstract:
碩士
國立中興大學
獸醫學系暨研究所
97
Abstract The present study investigates the influence of Huang-Lian-Jie-Du-Tang (HLJDT) and chemotherapy (CT) on BALB/cByNarl mice bearing CT-26 tumor cells. Mice were divided into two groups with (FOLFOX 4: 5-fluorouracil/leucovorin/oxaliplatin) or without chemotherapy. Each group was further divided into three subgroups: saline group, celebrex (cyclooxygenase-2 inhibitor) group and HLJDT group. HLJDT significantly inhibited the growth of tumor cells (Saline group tumor volume 1.66 ± 0.33cm3，HLJDT group 1.15 ± 0.27cm3,P＜0.05). Samller tumor size was found in HLJDT group after chemotherapy (CT group tumor volume 0.63 ± 0.27cm3，HLJDT combined CT group 0.32 ± 0.12cm3,P＜0.05). In combination of chemotherapy, the HLJDT group showed better results in tumor cells growth inhibition. Western blotting analysis showed that HLJDT inhibited tumor cells mitosis in PCNA level and increased caspase-3 amount, and suggesting an apoptosis promoting effect. COX-2 and β-catenin, two major marker proteins highly expressed in tumor cells, were significantly inhibited in HLJDT group. In conclusion this study showed that HLJDT could be helpful adjuvant in colorectal cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
10

Haruštiak, Tomáš. "Optimalizace předooperační a operační léčby karcinomu jícnu a ezfago-gatstrické junkce: využití PET/CT v diagnostice a hodnocení efektivity předoperační chemoterapie a technika konstrukce anastomozy jako faktor pooperačních komplikací po ezofagektomii." Doctoral thesis, 2017. http://www.nusl.cz/ntk/nusl-372353.

Full text
Abstract:
Key words: adenocarcinoma of the esophagus and esophagogastric junction, neoadjuvant chemotherapy, PET/CT, histopathological response, technique of esophagogastric anastomosis, anastomotic leak, anastomotic stricture Previous studies have shown that preoperative chemotherapy of locally advanced AEG is beneficial only for patients with a good histopathological response, the so-called responders. The aim of the first part of the thesis was to prospectively verify whether positron emission tomography (PET/CT) could be used for early identification of histopathological non- responders, who could be spared ineffective neoadjuvant treatment. Our study did not prove that the early metabolic response, expressed as the percentage change of the consumption of glucosis on PET/CT performed before (PET1) and 12 to 22 days after the start of the first cycle of preoperative chemotherapy (PET2) correlated with the histopathological response in the resection specimen in the entire population of 90 patients. In a post hoc explorative analysis we found the correlation between metabolic and histopathological response in a subgroup of patients with PET2 performed ≤16 days after the start of the therapy, but this hypothesis needs to be prospectively validated. Our study suggests that PET/CT performed after the first...
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Chemotherapy (CT)"

1

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Principles of chemotherapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0005.

Full text
Abstract:
Principles of radiation oncology outlines the physical and biological effects of ionising radiation, and its use in clinical oncology. Radiobiology, examining the response of tissue to ionising radiation, is described with regards to normal and malignant tissues. The effect of fractionation, the delivery of radiotherapy in a series of repeated exposures, is examined. The damaging effects on normal tissues are considered, particularly nonreversible late effects including carcinogenesis. Therapeutic exposure to ionising radiation is contrasted between radical and palliative radiotherapy. The physical properties of ionising radiation beams are described for superficial x-rays, megavoltage x-rays, and electrons. The process of treatment planning is summarised through beam dosimetry, target and critical organ outlining, dose planning, treatment verification, prescription and delivery. Computerised tomography is used for outlining and for verification, using cone beam CT. 0ther methods for image guided radiotherapy include fiducial markers. Increasingly intensity modulated radiotherapy is proving beneficial in reducing normal tissue damage during radical treatment. Stereotactic radiotherapy is used in the radical treatment of small unresectable malignancies. The clinical use of electron therapy, brachytherapy and intraoperative radiotherapy is described. Nuclear medicine uses unsealed radionuclides in imaging primary malignancies and their metastases, and in targeted radiotherapy. Examples include PET scanning, bone scanning, and radio iodine therapy. Whole body irradiation is used to improve outcomes after high-dose chemotherapy with stem cell or bone marrow transplantation.
APA, Harvard, Vancouver, ISO, and other styles
2

Dix, Philippa. Anaesthesia for radiology. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198719410.003.0031.

Full text
Abstract:
This chapter discusses the anaesthetic management of patients for computerized tomography (CT) or magnetic resonance imaging (MRI) scanning or interventional radiology procedures. It describes the particular hazards associated with the CT and MRI scanning rooms and recommends appropriate anaesthetic techniques. Interventional radiology procedures include angioplasty, stenting, embolization, chemotherapy, radiofrequency ablation, cryoablation, thrombolysis, and vertebroplasty or cementoplasty.
APA, Harvard, Vancouver, ISO, and other styles
3

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Madhumita Bhattacharyya. Skin cancers. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0023_update_001.

Full text
Abstract:
Tumours of the central nervous system examines the epidemiology, aetiology, genetics and pathology of these heterogeneous tumours. Clinical presentation reflects the site of origin and rate of growth. Investigation usually comprises imaging (MRI superior to CT for most), and biopsy; requirement for additional staging depends on pathology. The treatment of low-grade gliomas may be delayed if small with few symptoms, otherwise surgery and/or radiotherapy. High grade gliomas may be managed with surgery, radiotherapy, and temozolomide chemotherapy in fit patients. Unfit patients should be offered supportive care only. Brief summaries are provided for management of ependymoma, pineal tumours, meningioma, germ-cell CNS tumours, pituitary tumours, CNS lymphoma, acoustic neuroma, medulloblastoma, and spinal cord tumours. Radiotherapy for primary CNS tumours is described along with its side effects, and chemotherapy for these diseases is reviewed. Brain metastases far outnumber primary brain tumours, with generally poor prognosis, but this relates both to the pathology and patient performance status. Appropriate treatment may include surgery, radiotherapy, and/or chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Chemotherapy (CT)"

1

Zinser, J. W., R. Gaona, A. Mendoza, O. Ocampo, H. Domínguez-Malagón, E. Gómez, and L. Vicencio. "Advanced seminoma treated with chemotherapy (CT)." In Cancer Treatment An Update, 513–15. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Illarramendi, J. J., J. J. Valerdi, F. J. Dominguez, E. Martinez, and M. A. Dominguez. "Neo-Adjuvant chemotherapy (N-CT) followed by concomitant chemotherapy and radiotherapy (CC-CT) for locally advanced non-small cell lung cancer (NSCLC)." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 421–23. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_102.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Charnley, Natalie, Terry Jones, and Pat Price. "Principles of PET in Cancer Treatment for the Assessment of Chemotherapy and Radiotherapy Response and for Radiotherapy Treatment Planning." In Clinical PET-CT in Radiology, 157–62. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-48902-5_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Buthiau, D., D. Khayat, D. Nizri, J. Chantelard, M. Weil, J. P. Lefranc, and C. I. Jacquillat. "Follow-up of treated gynecologic cancer: CT and MRI contribution." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 297–301. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_73.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Seshadri, Nagabhushan, Rashika Fernando, and Radhakrishnan Jayan. "Conventional Radiological and PET-CT Assessment of Treatment Response Evaluation in Chemotherapy Setting." In Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology, 49–57. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-68858-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Balana, C., J. Minguell, B. Massuti, A. Arrivi, and B. Sanchez. "Treatment of locally advanced head and neck cancer with Neo-Adjuvant Cisplatin (CDDP) and 5-Fluorouracil (5-FU) chemotherapy (CT)." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 76–79. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kaira, Kyoichi. "PET-CT, Bio-imaging for Predicting Prognosis and Response to Chemotherapy in Patients with Lung Cancer." In Molecular Targeted Therapy of Lung Cancer, 45–61. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-2002-5_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Levy, R., J. M. Tourani, C. Le Maignan, P. Even, and J. M. Andrieu. "Initial intensive drug chemotherapy (CT) followed by extensive irradiation for limited small cell lung cancer (LSCLC). Improved response rate and survival. A pilot study." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 445–46. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rieber, A., H. J. Brambs, J. Görich, and G. W. Kauffmann. "Intraarterial Dynamic CT as a Control of Tumor-Perfusion before Regional Chemotherapy in Lung, Breast and Liver Cancers." In Computer Assisted Radiology / Computergestützte Radiologie, 826. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-662-00807-2_139.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Erazo, A., L. Torrecillas, G. Cervantes, and B. Ortega. "A phase II trial of Neo-Adjuvant chemotherapy (CT) with Ifosfamide (I), Mesna and Cisplatinum (C) in stage IIA-IIIB cervical cancer." In Cancer Treatment An Update, 485–87. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_102.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Chemotherapy (CT)"

1

Sequin, Emily K., Jennifer McFerran-Brock, Joseph West, and Vish Subramaniam. "Eddy Current Detection of Cancer in Surgically Excised Tissue." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53021.

Full text
Abstract:
In current clinical practice, a patient usually undergoes a diagnostic computer tomography (CT) scan for evaluation of specific presenting symptoms. The presence of cancer is then confirmed by a diagnostic biopsy or at surgical exploration by histopathologic analysis. Suspicious finding on the diagnostic CT scan may be followed by an 18F FDG (Fluorodeoxyglucose radiolabeled with 18F) positron emission tomography (PET) scan. In a majority of cases, these pre-operative CT and PET scans are used to identify the approximate location of the tumor(s) before surgical intervention. Surgery remains the most effective means of treating solid malignancies despite advances in chemotherapy and radiation therapy [1].
APA, Harvard, Vancouver, ISO, and other styles
2

Moghadas-Dastjerdi, Hadi, Hira R. Sha-E-Tallat, Lakshmanan Sannachi, Laurentius O. Osapoeta, Ali Sadeghi-Naini, and Gregory J. Czarnota. "Machine Learning-Based A Priori Chemotherapy Response Prediction in Breast Cancer Patients using Textural CT Biomarkers*." In 2020 42nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) in conjunction with the 43rd Annual Conference of the Canadian Medical and Biological Engineering Society. IEEE, 2020. http://dx.doi.org/10.1109/embc44109.2020.9176099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Giannini, Valentina, Arianna Defeudis, Samanta Rosati, Giovanni Cappello, Simone Mazzetti, Jovana Panic, Daniele Regge, and Gabriella Balestra. "An innovative radiomics approach to predict response to chemotherapy of liver metastases based on CT images." In 2020 42nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) in conjunction with the 43rd Annual Conference of the Canadian Medical and Biological Engineering Society. IEEE, 2020. http://dx.doi.org/10.1109/embc44109.2020.9176627.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Qiu, Yuchen, Maxine Tan, Scott McMeekin, Theresa Thai, Kathleen Moore, Kai Ding, Hong Liu, and Bin Zheng. "Evaluation of chemotherapy response in ovarian cancer treatment using quantitative CT image biomarkers: a preliminary study." In SPIE Medical Imaging, edited by Lubomir M. Hadjiiski and Georgia D. Tourassi. SPIE, 2015. http://dx.doi.org/10.1117/12.2081554.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Guerrero, Adriana, Jane Zhao, Xiaojie Yu, Alexander Pertsemlidis, and Andreas G. Bader. "Abstract 4829: miRNA combination therapy:In vitroanticancer synergy between miR-34a mimic and cytotoxic chemotherapy (CT) in NSCLC." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Badea, Cristian T., Ketan Ghaghada, Matthew D. Holbrook, Prajwal Bhandari, Darin P. Clark, Yi Qi, and Yvonne Mowery. "A spectral CT study on iodine augmentation of radiation therapy and its potential for combination with chemotherapy." In Biomedical Applications in Molecular, Structural, and Functional Imaging, edited by Barjor S. Gimi and Andrzej Krol. SPIE, 2020. http://dx.doi.org/10.1117/12.2549583.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Taplin, Mary-Ellen, Franklin Chu, Jodie P. Morrison, Roberto Pili, Matthew B. Rettig, Joe Stephenson, Nicholas J. Vogelzang, and R. Bruce Montgomery. "Abstract CT-07: ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC)." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-ct-07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Patt, D., J. Espirito, B. Turnwald, N. Denduluri, Y. Wang, A. Lina, R. Hoverman, et al. "Abstract P2-11-16: Cardiac Morbidity After Adjuvant Chemotherapy (CT) for Early Breast Cancer in the Community Setting." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p2-11-16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Defeudis, Arianna, Jovana Panic, Walter Guzzinati, Laura Pusceddu, Lorenzo Vassallo, Daniele Regge, and Valentina Giannini. "A Deep Learning model to segment liver metastases on CT images acquired at different time-points during chemotherapy." In 2022 IEEE International Symposium on Medical Measurements and Applications (MeMeA). IEEE, 2022. http://dx.doi.org/10.1109/memea54994.2022.9856589.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dinesh, A., VK Ramteke, J. Chander, M. Tripathi, and S. Mahajan. "Abstract P4-02-02: Comparison of 18F-FDG PET-CT and 11C-MET PET-CT for assessment of response to neoadjuvant chemotherapy in locally advanced breast carcinoma." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p4-02-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Chemotherapy (CT)"

1

Kengsakul, Malika, Gatske Nieuwenhuyzen – de Boer, and Heleen van Beekhuizen. Radiological factors associated with residual disease after cytoreductive surgery for advanced ovarian cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0059.

Full text
Abstract:
Review question / Objective: Which radiological factors associated with incomplete cytoreduction (gross residual disease) after cytoreductive surgery (CRS) for advanced ovarian cancer? Condition being studied: Findings of CT scan and discussion in the multidisciplinary tumor board meeting (MDO) are crucial to determine the therapeutic strategy for individual ovarian cancer patients. Preferably, patients undergo primary cytoreductive surgery (CRS) followed by adjuvant chemotherapy. However, when complete cytoreduction is not considered feasible, neoadjuvant chemotherapy followed by interval cytoreductive surgery and adjuvant chemotherapy is indicated. In patients with advanced stage epithelial ovarian cancer (EOC), maximal cytoreduction to no gross residual tumor (complete cytoreduction) is known to associated with the best overall survival.
APA, Harvard, Vancouver, ISO, and other styles
2

Wang, Min, Jiao Ma, Jiayu Zhang, Liyi Liu, Jia Wang, and Chunyin Zhang. The predictive value of 18F – FDG PET / CT maximum standardized uptake value change percentage for pathological complete response of breast cancer patients after neoadjuvant chemotherapy: Meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Chemotherapy (CT)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography